Discovery of 3-hydroxy-3-pyrrolin-2-one-based mPGES-1 inhibitors using a multi-step virtual screening protocol.

Targeting microsomal prostaglandin E2 synthase-1 (mPGES-1) represents an efficient strategy for the development of novel drugs against inflammation and cancer with potentially reduced side effects. With this aim, a virtual screening was performed on a large library of commercially available molecules using the X-ray structure of mPGES-1 co-complexed with a potent inhibitor. Combining fast ligand-based shape alignment, molecular docking experiments, and qualitative analysis of the binding poses, a small set of molecules was selected for the subsequent steps of validation of the biological activity. Compounds 2 and 3, bearing the 3-hydroxy-3-pyrrolin-2-one nucleus, showed mPGES-1-inhibitory activity in the low micromolar range. These data highlighted the applicability of the reported virtual screening protocol for the selection of new mPGES-1 inhibitors as promising anti-inflammatory/anti-cancer drugs.

[1]  E. Meuillet,et al.  Identification and development of mPGES-1 inhibitors: where we are at? , 2011, Future medicinal chemistry.

[2]  O. Werz,et al.  Design and Development of Microsomal Prostaglandin E2 Synthase-1 Inhibitors: Challenges and Future Directions. , 2016, Journal of medicinal chemistry.

[3]  E. Elinav,et al.  Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms , 2013, Nature Reviews Cancer.

[4]  G. Bifulco,et al.  Elucidating new structural features of the triazole scaffold for the development of mPGES-1 inhibitors , 2015 .

[5]  E. Loftus.  Epidemiology and risk factors for colorectal dysplasia and cancer in ulcerative colitis. , 2006, Gastroenterology clinics of North America.

[6]  V. Summa,et al.  4-Hydroxy-5-pyrrolinone-3-carboxamide HIV-1 integrase inhibitors. , 2008, Bioorganic & medicinal chemistry letters.

[7]  R. Riccio,et al.  Toward the Discovery of New Agents Able to Inhibit the Expression of Microsomal Prostaglandin E Synthase‐1 Enzyme as Promising Tools in Drug Development , 2010, Chemical biology & drug design.

[8]  S. Abramson,et al.  Prostaglandin E2 synthesis and secretion: the role of PGE2 synthases. , 2006, Clinical immunology.

[9]  G. Thomas,et al.  Patients with adenomatous polyps and carcinomas have increased colonic mucosal prostaglandin E2. , 1994, Gut.

[10]  G. Bifulco,et al.  Discovery of new potent molecular entities able to inhibit mPGES-1. , 2018, European journal of medicinal chemistry.

[11]  D. Rosenberg,et al.  mPGES-1 as a target for cancer suppression: A comprehensive invited review "Phospholipase A2 and lipid mediators". , 2010, Biochimie.

[12]  Ruiwen Zhang,et al.  Anti-Inflammatory Agents for Cancer Therapy. , 2009, Molecular and cellular pharmacology.

[13]  J. Luz,et al.  Crystal Structures of mPGES-1 Inhibitor Complexes Form a Basis for the Rational Design of Potent Analgesic and Anti-Inflammatory Therapeutics. , 2015, Journal of medicinal chemistry.

[14]  D. Rosenberg,et al.  Multifaceted roles of PGE2 in inflammation and cancer , 2012, Seminars in Immunopathology.

[15]  G. Bifulco,et al.  Structure-based discovery of inhibitors of microsomal prostaglandin E2 synthase-1, 5-lipoxygenase and 5-lipoxygenase-activating protein: promising hits for the development of new anti-inflammatory agents. , 2011, Journal of medicinal chemistry.

[16]  R. DuBois,et al.  PROSTAGLANDINS AND CANCER , 2005, Gut.

[17]  G. Bifulco,et al.  Structural Insights for the Optimization of Dihydropyrimidin-2(1H)-one Based mPGES-1 Inhibitors. , 2015, ACS medicinal chemistry letters.

[18]  Patrik Johansson,et al.  Crystal structure of microsomal prostaglandin E2 synthase provides insight into diversity in the MAPEG superfamily , 2013, Proceedings of the National Academy of Sciences.

[19]  Shobha N. Bhattachar,et al.  Discovery and Characterization of 2-Acylaminoimidazole Microsomal Prostaglandin E Synthase-1 Inhibitors. , 2016, Journal of medicinal chemistry.

[20]  G. Bifulco,et al.  Structure‐Based Design of Microsomal Prostaglandin E2 Synthase‐1 (mPGES‐1) Inhibitors using a Virtual Fragment Growing Optimization Scheme , 2016, ChemMedChem.

[21]  H. Kemona,et al.  From inflammation to cancer , 2016, Irish Journal of Medical Science (1971 -).

[22]  Woody Sherman,et al.  Boosting Virtual Screening Enrichments with Data Fusion: Coalescing Hits from Two-Dimensional Fingerprints, Shape, and Docking , 2013, J. Chem. Inf. Model..

[23]  Wolfgang Albrecht,et al.  Licofelone Suppresses Prostaglandin E2 Formation by Interference with the Inducible Microsomal Prostaglandin E2 Synthase-1 , 2008, Journal of Pharmacology and Experimental Therapeutics.

[24]  Á. Lanas,et al.  Adverse effects of non-steroidal anti-inflammatory drugs (NSAIDs, aspirin and coxibs) on upper gastrointestinal tract. , 2010, Best practice & research. Clinical gastroenterology.

[25]  O. Werz,et al.  Perspective of microsomal prostaglandin E2 synthase-1 as drug target in inflammation-related disorders. , 2015, Biochemical pharmacology.

[26]  B. Samuelsson,et al.  Microsomal prostaglandin E synthase‐1 and 5‐lipoxygenase: potential drug targets in cancer , 2010, Journal of internal medicine.

[27]  O. Werz,et al.  Inhibition of microsomal prostaglandin E2 synthase‐1 as a molecular basis for the anti‐inflammatory actions of boswellic acids from frankincense , 2011, British journal of pharmacology.

[28]  Woody Sherman,et al.  Structure-Based Virtual Screening of MT2 Melatonin Receptor: Influence of Template Choice and Structural Refinement , 2013, J. Chem. Inf. Model..

[29]  J. Pierce,et al.  Stereoselective Synthesis of Quaternary Pyrrolidine-2,3-diones and β-Amino Acids. , 2017, Organic letters.

[30]  L. Coussens,et al.  Inflammation and cancer , 2002, Nature.

[31]  M. Radi,et al.  A Combination Strategy to Inhibit Pim‐1: Synergism between Noncompetitive and ATP‐Competitive Inhibitors , 2013, ChemMedChem.

[32]  G. Bifulco,et al.  2,3-Dihydrobenzofuran privileged structures as new bioinspired lead compounds for the design of mPGES-1 inhibitors. , 2016, Bioorganic & medicinal chemistry.

[33]  Olivier Michielin,et al.  SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules , 2017, Scientific Reports.

[34]  M. Ståhle,et al.  Transition from inflammation to proliferation: a critical step during wound healing , 2016, Cellular and Molecular Life Sciences.

[35]  S. T. A. Shah,et al.  Crystallizing Membrane Proteins in the Lipidic Mesophase. Experience with Human Prostaglandin E2 Synthase 1 and an Evolving Strategy , 2014, Crystal growth & design.

[36]  G. Bifulco,et al.  Can Small Chemical Modifications of Natural Pan-inhibitors Modulate the Biological Selectivity? The Case of Curcumin Prenylated Derivatives Acting as HDAC or mPGES-1 Inhibitors. , 2015, Journal of natural products.

[37]  J. Lapointe,et al.  Impaired inflammatory and pain responses in mice lacking an inducible prostaglandin E synthase , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[38]  Ralf Morgenstern,et al.  Membrane Prostaglandin E Synthase-1: A Novel Therapeutic Target , 2007, Pharmacological Reviews.

[39]  F. Balkwill,et al.  Inflammation and cancer: advances and new agents , 2015, Nature Reviews Clinical Oncology.

[40]  G. Bifulco,et al.  Design and synthesis of a second series of triazole-based compounds as potent dual mPGES-1 and 5-lipoxygenase inhibitors. , 2012, European journal of medicinal chemistry.

[41]  S. Narumiya,et al.  Prostaglandin E Receptors* , 2007, Journal of Biological Chemistry.

[42]  J. Baell,et al.  New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. , 2010, Journal of medicinal chemistry.

[43]  J. Stanford,et al.  Self-report of prostatitis and its risk factors in a random sample of middle-aged men. , 2004, Urology.

[44]  M. Hamberg,et al.  A dynamic Asp–Arg interaction is essential for catalysis in microsomal prostaglandin E2 synthase , 2016, Proceedings of the National Academy of Sciences.

[45]  G. Kokotos,et al.  Microsomal prostaglandin E2 synthase-1 inhibitors: a patent review , 2017, Expert opinion on therapeutic patents.

[46]  J. Stanford,et al.  Sexual factors and the risk of prostate cancer. , 2001, American journal of epidemiology.

[47]  G. Bifulco,et al.  Identification of novel microsomal prostaglandin E2 synthase-1 (mPGES-1) lead inhibitors from Fragment Virtual Screening. , 2017, European journal of medicinal chemistry.

[48]  R. Murphy,et al.  The role of PGE2 in intestinal inflammation and tumorigenesis. , 2015, Prostaglandins & other lipid mediators.

[49]  Weiqi Wang,et al.  Synthesis and In Vitro Anti-Lung Cancer Activity of Novel 1, 3, 4, 8- Tetrahydropyrrolo (4, 3, 2-de)quinolin-8(1H)-o ne Alkaloid Analogs , 2009 .

[50]  Ezequiel Panepucci,et al.  Fast native-SAD phasing for routine macromolecular structure determination , 2014, Nature Methods.

[51]  C. Funk,et al.  Prostaglandins and leukotrienes: advances in eicosanoid biology. , 2001, Science.

[52]  X. Wan,et al.  Prostaglandin E2 (PGE2) promotes proliferation and invasion by enhancing SUMO-1 activity via EP4 receptor in endometrial cancer , 2016, Tumor Biology.

[53]  O. Werz,et al.  Identification of 5-lipoxygenase and microsomal prostaglandin E2 synthase-1 as functional targets of the anti-inflammatory and anti-carcinogenic garcinol. , 2009, Biochemical pharmacology.

[54]  G. Bifulco,et al.  Exploration of the dihydropyrimidine scaffold for the development of new potential anti-inflammatory agents blocking prostaglandin E₂ synthase-1 enzyme (mPGES-1). , 2014, European journal of medicinal chemistry.